現在地

松阪 諭(マツサカ サトシ; Matsusaka, Satoshi)

所属
医学医療系
職名
教授
職歴
2015-10 -- 2018-05がん研有明病院 消化器内科 がん研究所蛋白創製研究部兼任 医長
2013-10 -- 2015-09南カリフォルニア大学 腫瘍内科 ポスドクフェロー
2012-02 -- 2013-09がん研有明病院 消化器内科 医長
2006-04 -- 2012-01がん研有明病院 化学療法科 医員
2004-04 -- 2006-03山形大学 医学部医学科環境病態医学分野 助教
2002-04 -- 2003-03神戸大学 医学系研究科機能ゲノム学分野 COE研究員
2000-04 -- 2002-03宝塚市立病院 外科 医員
1994-04 -- 2000-03兵庫医科大学 第一外科 医員
その他の論文・記事
  • Intelligent Image-Activated Cell Sorting
    N Nitta; T Sugimura; A Isozaki; H Mikami; K Hiraki; S Sak...
    Cell/175(1)/pp.266-276, 2018-9
  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; F Loupakis; D Yang; C Cremolini; M Schirripa; M...
    Clin Colorectal Cancer./17(3)/pp.e471-e488, 2018-9
  • Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; M...
    Gastric Cancer/21(3)/pp.421-427, 2018-05
  • A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
    M Suenaga; T Akiyoshi; E Shinozaki; Y Fujimoto; S Matsusa...
    Anticancer Res/17(3)/pp.e471-e488, 2018-09
  • Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.
    Matsusaka S; Wu AH; Cao S; Hanna DL; Chin K; Yang D; Zhan...
    Pharmacogenomics J./18(2)/pp.262-269, 2018-04
  • A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
    MD Berger; S Stintzing; V Heinemann; S Cao; D Yang; Y Sun...
    Clin Cancer Res/24(4)/pp.784-793, 2018-02
  • A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
    MD Berger; S Stintzing; V Heinemann; S Cao; D Yang; Sunak...
    Clin Cancer Res/24(4)/pp.784-793, 2018-2
  • A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
    Sebio A; Stintzing S; Heinemann V; Sunakawa Y; Zhang W; I...
    Pharmacogenomics J./18(1)/pp.43-48, 2018-01
  • Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.
    Sunakawa Y; Cao S; Volz NB; Berger MD; Yang D; Parekh A; ...
    Pharmacogenomics J./17(6)/pp.528-534, 2017-12
  • CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
    松阪 諭; Cao S Hanna DL; Hanna DL; Sunakawa Y; Ueno M; Mi...
    Pharmacogenomics J./17(6)/pp.543-550, 2017-12
  • Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunak...
    Ann Oncol/28(11)/pp.2780-2785, 2017-11
  • Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
    Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N;...
    Pathol Oncol Res./23(4)/pp.737-744, 2017-10
  • Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
    Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang ...
    Int J Cancer/141(6)/pp.1222-1230, 2017-09
  • Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
    Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Tak...
    Target Oncol./12(3)/pp.341-351, 2017-06
  • Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    Berger MD; Yamauchi S; Cao S; Hanna DL; Sunakawa Y; Schir...
    Eur J Cancer./77/pp.13-20, 2017-05
  • A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsu...
    Gastric Cancer./20(2)/pp.350-357, 2017-03
  • Genetic variants associated with colorectal brain metastases susceptibility and survival.
    Stremitzer S; Berghoff AS; Volz NB; Zhang W; Yang D; Stin...
    Pharmacogenomics J./17(1)/pp.29-35, 2017-01
  • Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.
    Y Sunakawa; S Cao; MD Berger; S Matsusaka; D Yang; Zhang ...
    Pharmacogenomics J/17(1)/pp.36-41, 2017-01
  • Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
    松阪 諭; T Kobunai; N Yamamoto; K Chin; M Ogura; G Tanaka...
    Genes Cancer/7(1-2)/pp.27-35, 2016
  • Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
    Matsusaka Satoshi; S Matsusaka; W Zhang; D Yang; Y Ning; ...
    Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer./16(4)/pp.312-319, 2016
  • Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
    H Osumi; T Yoshio; K Chin; M Ogura; Y Kumekawa; M Suenaga...
    Gastric Cancer./19(2)/pp.625-630, 2016
  • TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.
    松阪 諭; Zhang W; Cao S; Hanna DL; Sunakawa Y; Sebio A; U...
    Mol Cancer Ther/15(6)/pp.1405-1411, 2016
  • Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
    Matsusaka Satoshi; DL Hanna; S Cao; W Zhang; D Yang; Y Ni...
    Clin Cancer Res/22(13)/pp.3218-3126, 2016
  • Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
    Matsusaka Satoshi; A Nashimoto; K Nishikawa; A Miki; H Mi...
    Gastric Cancer/19(3)/pp.839-851, 2016
  • Letter in response to "Our HER2 is same as yours"
    松阪 諭; Yoshida K
    Transl Gastroenterol Hepatol/1/pp.18-18, 2016
著書
  • Biomarker for chemotherapy in patients with colorectal cancer
    松阪 諭
    Gan To Kagaku Ryoho, pp.11-4, 2009
  • 抗体医薬に対するバイオマーカー-末梢循環癌細胞(CTC), 末梢循環血管内皮細胞(CEC), 末梢循環血管内皮前駆細胞(CEP)
    松阪 諭
    医学のあゆみ, pp.1105-1108, 2009
  • CTCによるトランスレーショナルリサーチ
    松阪 諭; 三嶋雄二; 畠精彦
    細胞工学別冊, pp.176-179, 2010
  • 末梢循環血管内皮細胞(CEC)と末梢循環血管内皮前駆細胞(CEP)
    松阪 諭
    最新医学, pp.461-469, 2011
  • 末梢循環血管内皮細胞(CEC)と末梢循環血管内皮前駆細胞(CEP)
    松阪 諭
    最新医学, pp.461-469, 2011
  • 大腸癌補助化学療法におけるオキサリプラチン使用の是非 肯定派
    松阪 諭
    Frontiers in Gastroenterology, pp.332-338, 2012
  • 微量癌細胞検出の臨床的意義〜腫瘍内科医の立場から
    松阪 諭; 畠精彦
    大腸癌FRONTIER, pp.14-19, 2012
  • リキッドバイオプシー-がんにおける臨床応用と将来展望
    松阪 諭
    医学のあゆみ, pp.999-1003, 2018
  • CTC (Circulating tumor cell) -分子標的治療薬における臨床応用
    松阪 諭
    医学のあゆみ, pp.18407-18411, 2018

(最終更新日: 2018-11-16)